GSK-340

• Description :

  GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide (HY-D1056) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity[1].

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain

• Related Pathways :

  Epigenetics

• Field of Research :

  Inflammation/Immunology

• Smiles :

  CC(N1[C@@H](C2CC2)CN(CC3=CC=CC=C3CO)C4=C1C=CC(C5=CCNCC5)=C4)=O

• Molecular Formula :

  C26H31N3O2

• Molecular Weight :

  417.54

• References & Citations :

  [1]Law RP, et al. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem. 2018 May 24;61 (10) :4317-4334.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2222509-79-5]